A randomized, placebo-controlled, double-blinded Phase III trial of XmAb5871 in IgG4-RD
Phase of Trial: Phase III
Latest Information Update: 14 Nov 2017
At a glance
- Drugs XmAb 5871 (Primary)
- Indications Immunological disorders
- Focus Therapeutic Use
- 14 Nov 2017 New trial record
- 07 Nov 2017 According to a Xencor media release, the company met with the Division of Pulmonary, Allergy and Respiratory Products (DPARP) of FDA to discuss this trial.
- 07 Nov 2017 According to a Xencor media release, this trial is planned to initiate 2H18.